SMS PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 207.2 INR | -0.34% |
|
-3.18% | +74.59% |
| Sales 2022 | 5.2B 62.31M 85.15M | Sales 2023 | 5.22B 62.57M 85.5M | Capitalization | 4.93B 59.1M 80.76M |
|---|---|---|---|---|---|
| Net income 2022 | 622M 7.46M 10.19M | Net income 2023 | -70M -839K -1.15M | EV / Sales 2022 | 1.94 x |
| Net Debt 2022 | 2.17B 25.97M 35.49M | Net Debt 2023 | 2.47B 29.57M 40.4M | EV / Sales 2023 | 1.42 x |
| P/E ratio 2022 |
12.7
x | P/E ratio 2023 |
-69.9
x | Employees | 1,095 |
| Yield 2022 |
0.32% | Yield 2023 |
0.52% | Free-Float | 27.62% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.34% | ||
| 1 week | -3.18% | ||
| Current month | +16.34% | ||
| 1 month | +16.34% | ||
| 3 months | +68.96% | ||
| 6 months | +74.52% | ||
| Current year | +74.59% |
1 week
206.00
215.75
1 month
178.20219.30
Current year
119.80219.30
1 year
75.10219.30
3 years
54.50219.30
5 years
23.55219.30
10 years
23.55219.30
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 90-08-29 | |
| Director of Finance/CFO | - | 17-09-12 | |
Tirumalesh Tumma
CMP | Compliance Officer | - | 22-02-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 90-08-29 | |
| Director/Board Member | 60 | 19-08-11 | |
| Director/Board Member | 67 | 14-08-11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 207.2 | -0.34% | 71,117 |
| 24-04-26 | 207.8 | -0.31% | 46,141 |
| 24-04-25 | 208.5 | -0.10% | 34,918 |
| 24-04-24 | 208.7 | -1.25% | 32,791 |
| 24-04-23 | 211.4 | -1.22% | 19,691 |
Delayed Quote Bombay S.E., April 29, 2024 at 06:00 am
More quotes
SMS Pharmaceuticals Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in the business of manufacturing of active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic and others. The Company products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel and lamotrigine. The Company has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.
Sector
Pharmaceuticals
Calendar
2024-05-23
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +20.81% | 43.34B | |
| +21.21% | 21.96B | |
| +13.30% | 14.09B | |
| +12.97% | 13.64B | |
| +39.74% | 11.43B | |
| -10.83% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +9.64% | 5.22B |
- Stock Market
- Equities
- SMSPHARMA Stock
- 532815 Stock
